132 results
8-K
EX-99.2
LUMO
Lumos Pharma Inc
15 May 24
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
9:57am
for up to 3 yearsPlacebo control 6 months N ~50 Cross to 1.6 g/ g/ ay 1 6 s LTSE = Long-term Safety Extension Cross-over from placebo to LUM-201
8-K
EX-99.1
LUMO
Lumos Pharma Inc
15 May 24
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
9:57am
Total current liabilities
Long-term liabilities:
Royalty obligation payable to Iowa Economic Development Authority
Lease liability
Total liabilities
8-K
EX-99.1
udiahhy32
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
8-K
EX-99.1
5hmbi311o60
15 Nov 23
Other Events
4:38pm
8-K
EX-99.1
rk4vuzxio 8uqap6t9
7 Nov 23
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
4:42pm
8-K
EX-99.1
h458beoagjzzx22x
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
EX-99.2
6xw02krm3wn1yqs72wi
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm
8-K
EX-99.1
e84ndqb81 ukpe9
3 May 23
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
4:49pm
8-K
EX-99.1
82n3rc
14 Nov 22
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
7:29am
8-K
EX-99.2
gjoebo1
14 Nov 22
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
6:55am
8-K
EX-99.1
kria yi1y4iz4
10 Aug 22
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
12:00am